Terms: = Prostate cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Diagnosis
24 results:
1. Treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
2. Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential.
Ragavi R; Muthukumaran P; Nandagopal S; Ahirwar DK; Tomo S; Misra S; Guerriero G; Shukla KK
Urol Oncol; 2023 Aug; 41(8):340-353. PubMed ID: 37032230
[TBL] [Abstract] [Full Text] [Related]
3. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling.
Entezari M; Ghanbarirad M; Taheriazam A; Sadrkhanloo M; Zabolian A; Goharrizi MASB; Hushmandi K; Aref AR; Ashrafizadeh M; Zarrabi A; Nabavi N; Rabiee N; Hashemi M; Samarghandian S
Biomed Pharmacother; 2022 Jun; 150():112963. PubMed ID: 35468579
[TBL] [Abstract] [Full Text] [Related]
4. LINC00963: A potential cancer diagnostic and therapeutic target.
Xie Z; Zhong C; Shen J; Jia Y; Duan S
Biomed Pharmacother; 2022 Jun; 150():113019. PubMed ID: 35462329
[TBL] [Abstract] [Full Text] [Related]
5. STAT3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression.
Zhu W; Sheng D; Shao Y; Zhang Q; Peng Y
Mol Cell Biochem; 2022 Mar; 477(3):865-875. PubMed ID: 35067783
[TBL] [Abstract] [Full Text] [Related]
6. A Poly-vinyl Alcohol (PVA)-based phantom and training tool for use in simulated Transrectal Ultrasound (TRUS) guided prostate needle biopsy procedures.
Gautam UC; Pydi YS; Selladurai S; Das CJ; Thittai AK; Roy S; Datla NV
Med Eng Phys; 2021 Oct; 96():46-52. PubMed ID: 34565552
[TBL] [Abstract] [Full Text] [Related]
7. prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
Yamoah K; Asamoah FA; Abrahams AOD; Awasthi S; Mensah JE; Dhillon J; Mahal BA; Gueye SM; Jalloh M; Farahani SJ; Lal P; Rebbeck TR; Yarney J
Prostate; 2021 Dec; 81(16):1402-1410. PubMed ID: 34529278
[TBL] [Abstract] [Full Text] [Related]
8. The Role of Tumor-related LncRNA PART1 in cancer.
Chen J; Meng E; Lin Y; Shen Y; Hu C; Zhou G; Yuan C
Curr Pharm Des; 2021; 27(40):4152-4159. PubMed ID: 34225608
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and Biological Features of Neuroendocrine prostate cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract] [Full Text] [Related]
10. MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in prostate cancer.
Aghdam AM; Amiri A; Salarinia R; Masoudifar A; Ghasemi F; Mirzaei H
Crit Rev Eukaryot Gene Expr; 2019; 29(2):127-139. PubMed ID: 31679268
[TBL] [Abstract] [Full Text] [Related]
11. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
12. Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels.
Huang J; Deng G; Liu T; Chen W; Zhou Y
Biochem Biophys Res Commun; 2018 Jan; 495(4):2622-2629. PubMed ID: 29291409
[TBL] [Abstract] [Full Text] [Related]
13. High immunoexpression of Ki67, ezh2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract] [Full Text] [Related]
14. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
[TBL] [Abstract] [Full Text] [Related]
15. cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and ezh2.
Matsika A; Srinivasan B; Day C; Mader SA; Kiernan DM; Broomfield A; Fu J; Hooper JD; Kench JG; Samaratunga H
Pathology; 2015 Dec; 47(7):622-8. PubMed ID: 26517640
[TBL] [Abstract] [Full Text] [Related]
16. A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a prostate cancer Aggressive Phenotype.
Zhu G; Liu Z; Epstein JI; Davis C; Christudass CS; Carter HB; Landis P; Zhang H; Chung JY; Hewitt SM; Miller MC; Veltri RW
Cancer Epidemiol Biomarkers Prev; 2015 Dec; 24(12):1864-72. PubMed ID: 26404961
[TBL] [Abstract] [Full Text] [Related]
17. Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2014 May; 24(3):303-10. PubMed ID: 24625431
[TBL] [Abstract] [Full Text] [Related]
18. Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer.
Yocum AK; Khan AP; Zhao R; Chinnaiyan AM
Proteomics; 2010 Oct; 10(19):3506-14. PubMed ID: 20821805
[TBL] [Abstract] [Full Text] [Related]
19. [Molecular genetic markers for prostate cancer. Evidence in fine needle biopsies for improved confirmation of the diagnosis].
Schneider S; Voigt S; Füssel S; Lohse-Fischer A; Tomasetti S; Haase M; Koch R; Baretton GB; Grimm MO; Wirth M
Urologe A; 2008 Sep; 47(9):1208-11. PubMed ID: 18679647
[TBL] [Abstract] [Full Text] [Related]
20. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.
van Gils MP; Hessels D; Hulsbergen-van de Kaa CA; Witjes JA; Jansen CF; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2008 Aug; 68(11):1215-22. PubMed ID: 18500693
[TBL] [Abstract] [Full Text] [Related]
[Next]
